Aytu biopharma announces agreement with avenue venture debt fund to extend interest-only period of company's term loan

Amendment of secured loan agreement extends interest-only period to january 2024 amendment defers over $3 million in principal payments beyond 2023 note matures in january 2025, with additional extensions of the interest-only period available, subject to achievement of certain milestones englewood, co / accesswire / october 25, 2022 / aytu biopharma, inc. (the company or "aytu") (nasdaq:aytu), a pharmaceutical company focused on commercializing novel therapeutics, today announced an agreement with the avenue venture opportunities fund, l.p. ("avenue venture debt fund" or "avenue") to extend the interest-only period of the company's existing senior secured loan facility held with avenue.
AYTU Ratings Summary
AYTU Quant Ranking